May. 16 2024
Source Page: PACE Codes H and I 2024Found: has in their possession, or claims to need, medication relating to a heart condition, diabetes, epilepsy
May. 16 2024
Source Page: PACE Codes H and I 2024Found: detainee has in their possession, or claims to need, medication relating to a heart condition, diabetes, epilepsy
Mentions:
1: Baroness Andrews (Lab - Life peer) The child has, among other chronic conditions, epilepsy, and so she cannot travel alone.The parents, - Speech Link
Written Evidence May. 15 2024
Inquiry: Climate change and securityFound: epilepsy) is poorly understood.
May. 15 2024
Source Page: Class 4 Medicines Defect Information: Doncaster Pharma Limited, Keppra 500mg film-coated tablets, EL(24)A/15Found: Suddenly stopping an epilepsy medicine may cause your seizures to start again or happen more often or
May. 13 2024
Source Page: UK service personnel medical discharges: financial year 2022/23Found: 7 22 6 - Of which adjustment disorder 31 2 8 2 Nervous system disorders 82 4 16 4 - Of which epilepsy
May. 13 2024
Source Page: UK service personnel medical discharges: financial year 2022/23Found: 1 [c] less than 1 8 2 Nervous system disorders G00 to G99 82 4 15 4 20 5 13 4 18 4 16 4 - Of which epilepsy
Asked by: Catherine West (Labour - Hornsey and Wood Green)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with Novartis on the adequacy of supply of the epilepsy medication Tegretol.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department has been working intensively to address issues with the supply of some epilepsy medications, and as a result we have helped to resolve issues with Tegretol 200 milligram and 400 milligram prolonged release tablets, and Tegretol 100 milligram immediate release tablets. We are aware of a shortage of Tegretol 100 milligram/5 millilitre liquid, but have been advised that resupplies are expected this month. We are continuing to work closely with manufacturers, including Novartis, to help ensure the continued supply of these medicines for patients in the United Kingdom, for example by asking suppliers to expedite deliveries.
Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.
Found: shortages of medicines used to treat diabetes, attention deficit hyperactivity disorder (ADHD) and epilepsy
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with the Medicines and Healthcare products Regulatory Agency on (a) its advice on prescribing and (b) the side effects of gabapentin.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Gabapentin is authorised for the treatment of some forms of epilepsy, as well as peripheral neuropathic pain. The product information for gabapentin, approved by the Medicines and Healthcare products Regulatory Agency (MHRA), provides information to support the prescribing of the medication including recommendations for dose, duration of use, as well as gradual reduction when stopping. The product information includes warnings about possible side effects.
The MHRA continuously monitors the safety of gabapentin and ensures the product information reflects what is known about the medicine and its side effects.